Barry O'Brien

Dr. Barry O'Brien


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SASahar Avazzadeh
Sahar Avazzadeh
SMShauna McBride
Shauna McBride
BOBarry O'Brien
Barry O'Brien
KCKen Coffey
Ken Coffey
AEAdnan Elahi
Adnan Elahi
LQLeo Quinlan
Leo Quinlan
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with significant morbidity and mortality. The autonomic nervous system (ANS) plays an important role in the initiation and development of AF, causing alterations in atrial structure and electrophysiological defects. The intrinsic ANS of the heart consists of multiple ganglionated plexi (GP), commonly nestled in epicardial fat pads. These GPs contain both parasympathetic and sympathetic afferent and efferent neuronal circuits that control the electrophysiological properties of the myocardium. Pulmonary vein isolation and other cardiac catheter ablation targets including GP ablation can disrupt the fibers connecting GPs or directly damage the GPs, mediating the benefits of the ablation procedure. Ablation of GPs has been evaluated over the past decade as an adjunctive procedure for the treatment of patients suffering from AF. The success rate of GP ablation is strongly associated with specific ablation sites, surgical techniques, localization techniques, method of access and the incorporation of additional interventions. In this review, we present the current data on the clinical utility of GP ablation and its significance in AF elimination and the restoration of normal sinus rhythm in humans.

Verified
Journal Article
Open access
PDF file
SMShauna McBride
Shauna McBride
SASahar Avazzadeh
Sahar Avazzadeh
AWAntony Wheatley
Antony Wheatley
BOBarry O'Brien
Barry O'Brien
KCKen Coffey
Ken Coffey
LQLeo Quinlan
Leo Quinlan
Targeted cellular ablation is being increasingly used in the treatment of arrhythmias and structural heart disease. Catheter-based ablation for atrial fibrillation (AF) is considered a safe and effective approach for patients who are medication refractory. Electroporation (EPo) employs electrical energy to disrupt cell membranes which has a minimally thermal effect. The nanopores that arise from EPo can be temporary or permanent. Reversible electroporation is transitory in nature and cell viability is maintained, whereas irreversible electroporation causes permanent pore formation, leading to loss of cellular homeostasis and cell death. Several studies report that EPo displays a degree of specificity in terms of the lethal threshold required to induce cell death in different tissues. However, significantly more research is required to scope the profile of EPo thresholds for specific cell types within complex tissues. Irreversible electroporation (IRE) as an ablative approach appears to overcome the significant negative effects associated with thermal based techniques, particularly collateral damage to surrounding structures. With further fine-tuning of parameters and longer and larger clinical trials, EPo may lead the way of adapting a safer and efficient ablation modality for the treatment of persistent AF.

BOBarry O'Brien
Barry O'Brien
JRJohn Reilly
John Reilly
KCKen Coffey
Ken Coffey
Ana González-SuárezAna González-Suárez
Ana González-Suárez
LQLeo Quinlan
Leo Quinlan
MZMartin van Zyl
Martin van Zyl
Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people worldwide. The cardiac autonomic nervous system (ANS) is widely recognized as playing a key role in both the initiation and propagation of AF. This paper reviews the background and development of a unique cardioneuroablation technique for the modulation of the cardiac ANS as a potential treatment for AF. The treatment uses pulsed electric field energy to selectively electroporate ANS structures on the epicardial surface of the heart. Insights from in vitro studies and electric field models are presented as well as data from both pre-clinical and early clinical studies.

16 April 2024 in Computers in Biology and Medicine
Verified
Journal Article
Open access
FEFrancisco Estevez-Laborí
Francisco Estevez-Laborí
BOBarry O'Brien
Barry O'Brien
Ana González-SuárezAna González-Suárez
Ana González-Suárez
Pulsed Field Ablation (PFA) has recently been proposed as a non-thermal energy to treat atrial fibrillation by selective ablation of ganglionated plexi (GP) embedded in epicardial fat. While some of PFA-technologies use an endocardial approach, others use epicardial access with promising pre-clinical results. However, as each technology uses a different and sometimes proprietary pulse application protocol, the comparation between endocardial vs. epicardial approach is almost impossible in experimental terms. For this reason, our study, based on a computational model, allows a direct comparison of electric field distribution and thermal-side effects of both approaches under equal conditions in terms of electrode design, pulse protocol and anatomical characteristics of the tissues involved. 2D computational models with axial symmetry were built for endocardial and epicardial approaches. Atrial (1.5-2.5 mm) and fat (1-5 mm) thicknesses were varied to simulate a representative sample of what happens during PFA ablation for different applied voltage values (1000, 1500 and 2000 V) and number of pulses (30 and 50). The epicardial approach was superior for capturing greater volumes of fat when the applied voltage was increased: 231 mm3/kV with the epicardial approach vs. 182 mm3/kV with the endocardial approach. In relation to collateral damage to the myocardium, the epicardial approach considerably spares the myocardium, unlike what happens with the endocardial approach. Although the epicardial approach caused much more thermal damage in the fat, there is not a significant difference between the approaches in terms of size of thermal damage in the myocardium. Our results suggest that epicardial PFA ablation of GPs is more effective than an endocardial approach. The proximity and directionality of the electric field deposited using an epicardial approach are key to ensuring that higher electric field strengths and increased temperatures are obtained within the epicardial fat, thus contributing to selective ablation of the GPs with minimal myocardial damage.

24 December 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
BOBarry O'Brien
Barry O'Brien
JRJohn Reilly
John Reilly
KCKen Coffey
Ken Coffey
Ana González-SuárezAna González-Suárez
Ana González-Suárez
PBPiotr Buchta
Piotr Buchta
SASamuel Asirvatham
Samuel Asirvatham
Epicardial pulsed field ablation (PFA) of ganglionated plexi (GPs) is being explored as a potential treatment for atrial fibrillation. Initial work using open-chest access with a monopolar ablation device has been completed. This study describes the early development work for a device that can be used with subxiphoid access and deliver bipolar ablation pulses. Electric field computational models have been used for the initial guidance on pulse parameters. An in vivo assessment of these ablation parameters has been performed in an open-chest canine study, while subxiphoid access and navigation of the device has been demonstrated in a porcine model. Results from this acute study have demonstrated the promising potential of this approach.

17 July 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
FEFrancisco Estevez-Labori
Francisco Estevez-Labori
MIMaite Izquierdo
Maite Izquierdo
KCKen Coffey
Ken Coffey
BOBarry O'Brien
Barry O'Brien
Ana González-SuárezAna González-Suárez
Ana González-Suárez
Background: Current ablation strategies for the treatment of cardiac arrhythmias remain suboptimal. Treating cardiac arrhythmias using epicardial pulsed field ablation (PFA) selectively targets ganglionated plexi (GPs) within epicardial fat, offering a promising alternative to thermal ablation. Previous computational studies lacked physiological realism, excluding catheter geometry, fluid flow and post-PFA thermal latency. This study aimed to develop a realistic 3D epicardial PFA model integrating a clinical catheter, clinical PFA parameters and a sequentially coupled electro-thermal-fluid dynamics model, including thermal latency, to assess electrical and thermal collateral effects near stented coronary arteries. Methods: The model included epicardial fat, myocardium, blood, and the left circumflex artery containing a metallic stent positioned 0.25 mm beneath the catheter electrodes. Pulses of 1000, 2000, and 2500 V (60 pulses × 100 µs, 1 Hz) were simulated to analyze electric field distribution, PFA-induced lesion volume, temperature evolution, and Arrhenius-based thermal damage, including a 90 s post-pulse period to account for thermal latency. The PFA-threshold of 1000 V/cm was considered. Results: The artery reduced PFA-induced lesion size mainly by occupying fat tissue volume, while the stent shielded the lumen without altering fat lesion volume. The presence of a stent produced localized electric field enhancement at the arterial wall, with up to 3.83% of the arterial wall volume affected by PFA in the worst-case configuration. At clinical settings (1000 V), temperature remained below 40 °C and no collateral damage occurred. Voltages > 2000 V increased arterial wall heating, with thermal damage expanding up to five-fold during latency in the epicardial fat. Myocardium remained unaffected in all cases. Conclusions: The computational model developed in this study indicates that clinically relevant PFA parameters (1000 V) produce localized electric field enhancement at the stent–artery interface, resulting in limited collateral electrical effects in the arterial wall, while avoiding collateral thermal effects and preserving the myocardium. However, the use of higher pulse voltages can lead to delayed thermal damage within the epicardial fat.